Invivyd Stock Price, News & Analysis

Invivyd (Nasdaq: IVVD) announced its participation in two upcoming investor conferences in New York. The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, 2025, at 2:10 PM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 12:00 PM ET.

The presentations will be available via live webcasts on the company's investor website and archived for approximately 30 days. Management will also host investor meetings during both conferences.

Invivyd (Nasdaq: IVVD) has successfully closed its public offering, raising $57.5 million in gross proceeds. The offering included 89.2 million shares of common stock at $0.52 per share and 21.3 million pre-funded warrants at $0.5199 each. The underwriter, Cantor, fully exercised its option to purchase an additional 14.4 million shares.

The financing was led by RA Capital Management and Janus Henderson Investors. Funds will support the VYD2311 clinical program, research in RSV and measles, and advancement of the SPEAR Study Group's efforts regarding Long COVID and COVID-19 Post-Vaccination Syndrome treatments.

Invivyd (Nasdaq: IVVD) has announced the pricing of a $50 million public offering, consisting of 74,811,404 shares of common stock at $0.52 per share and pre-funded warrants for 21,342,442 shares at $0.5199 per warrant.

The company has granted underwriters a 30-day option to purchase up to 14,423,076 additional shares. The offering, managed by Cantor as sole book-runner, is expected to close around August 22, 2025. Proceeds will fund the VYD2311 clinical program, research in RSV and measles, SPEAR Study Group efforts for Long COVID research, and general corporate purposes.

Invivyd (Nasdaq: IVVD) has announced a proposed underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price. Cantor will serve as the sole book-running manager.

The proceeds will fund multiple initiatives including the VYD2311 clinical program, research and development of pipeline programs for RSV and measles, and advancement of the SPEAR Study Group's research on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome. The offering will be made through a shelf registration statement previously filed with the SEC.

Invivyd (NASDAQ:IVVD) has announced that its COVID-19 antibody PEMGARDA® (pemivibart) and its next-generation candidate VYD2311 maintain strong neutralizing activity against the dominant XFG ("Stratus") SARS-CoV-2 variant. The company reports that COVID-19 cases are rising, with high viral activity in 12 states and growing infections in 34 states according to CDC data.

PEMGARDA, which is FDA-authorized for pre-exposure prophylaxis in certain immunocompromised patients, has demonstrated consistent effectiveness against all clinical variants since the Omicron BA.2 lineage. The company will submit new in vitro neutralization data to the FDA for inclusion in PEMGARDA's Healthcare Provider Fact Sheet.

Invivyd (NASDAQ: IVVD) reported Q2 2025 financial results, highlighting $11.8 million in PEMGARDA® net product revenue, representing 413% year-over-year growth. The company announced positive Phase 1/2 data for VYD2311, their COVID-19 monoclonal antibody candidate, demonstrating favorable safety and a 76-day half-life for intramuscular administration.

The FDA has aligned on a rapid pathway to full approval (BLA) for VYD2311. The company's pipeline expansion includes RSV and measles candidates, with updates expected in Q3 and Q4 2025. Financial results showed a net loss of $14.7 million ($0.12 per share), improved from $47.2 million loss in Q2 2024, with $34.9 million in cash as of June 30, 2025.

Invivyd (NASDAQ: IVVD) has received FDA alignment on a streamlined pathway to potential BLA approval for VYD2311, its monoclonal antibody candidate for COVID-19 prevention. The FDA advised that a single Phase 2/3 randomized, double-blind, placebo-controlled trial could support BLA submission for broad population use (12+ years, 40kg+).

The clinical trial will evaluate two doses of VYD2311, featuring a 12-week primary endpoint analysis with potential extension to 24 weeks. The antibody demonstrates promising characteristics including a ~76-day half-life and high potency. The company positions VYD2311 as a non-vaccine alternative for COVID-19 prevention, targeting both immunocompromised individuals and the general population seeking protection.

Invivyd (Nasdaq: IVVD) has announced that Dr. Akiko Iwasaki, Professor of Immunobiology at Yale School of Medicine, has joined the SPEAR Study Group. The group was established to investigate the biology and clinical implications of persistent spike protein from SARS-CoV-2 virus and COVID-19 vaccines.

Dr. Iwasaki, co-Lead Investigator of the Yale COVID-19 Recovery Study, brings expertise in viral pathogenesis and post-viral conditions. The SPEAR Study Group was formed following reports that PEMGARDA® (pemivibart), Invivyd's FDA-authorized monoclonal antibody, showed potential benefits in Long COVID cases. The group plans to conduct clinical trials to evaluate monoclonal antibodies, including VYD2311, for treating Long COVID and Post-Vaccination Syndrome (PVS).

Invivyd (NASDAQ: IVVD) announced that the National Comprehensive Cancer Network (NCCN) has updated its guidelines to recommend monoclonal antibodies for COVID-19 prevention in cancer patients. This update aligns with guidance from IDSA and CDC, highlighting the importance of protecting immunocompromised individuals.

New research published in JAMA Oncology from the National Cancer Institute's study of 1,572 cancer patients with COVID-19 revealed concerning findings: high hospitalization rates, treatment disruptions, and significant complications. Notably, over 50% of cancer treatment disruptions were directly attributed to COVID-19, and of 290 initially hospitalized patients, 31 required readmission within 30 days for COVID-19 complications.